ReviewExpert opinion on drug discovery2013
Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs.
Review in Expert opinion on drug discovery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed.
- Emerging antifungal strategies against Candida albicans using metal-organic frameworks and novel therapeutics: Opportunities and challenges.Journal of food and drug analysis · 2026Review
- High throughput screen reveals four compounds with novel antifungal activity, including a metal-responsive candidate with in vivo efficacy against Candida albicans.Scientific reports · 2026Article
- Inhibition of Candida albicans yeast-to-hypha transition and virulence by cyclic dipeptides derived from probiotic Aeromonas veronii V03.Scientific reports · 2026Article
- Article
- Inhibitory effect and safety of Angelica dahurica-Ligusticum sinense extracts against Malassezia furfur and its biofilms.PloS one · 2026Article
- α-Glucosidase-driven metabolism as a potential therapeutic vulnerability inFrontiers in microbiology · 2026Review
- How nettle (Journal of biosciences · 2026Article
- Structural Optimization of Antifungal Peptoids targetingACS medicinal chemistry letters · 2025Article
- The adaptability of the fungal tRNA ligase's ATP-binding pocket: a potential target for new antifungal drugs.NAR molecular medicine · 2025Article
- A Novel Benzopyrone Derivative from Streptomyces chrestomyceticus ADP4 Inhibits Growth and Virulence Factors of Candida albicans.Current microbiology · 2025Article
- Impact of Clove Oil on Biofilm Formation inMycobiology · 2025Article
- Article
- The impacts of animal agriculture on One Health-Bacterial zoonosis, antimicrobial resistance, and beyond.One health (Amsterdam, Netherlands) · 2024Review
- Mitigating candidiasis with acarbose by targeting Candida albicans α-glucosidase: in-silico, in-vitro and transcriptomic approaches.Scientific reports · 2024Article
- Antibiofilm Activity of Curcumin and Piperine and Their Synergistic Effects with Antifungals againstScientifica · 2024Article
- Curcumin nanoparticles: the topical antimycotic suspension treating oral candidiasis.Odontology · 2023Article
- Potential Anti-International journal of molecular sciences · 2023Article
- Chemical Profile, Anti-Microbial and Anti-Inflammaging Activities ofAntibiotics (Basel, Switzerland) · 2023Article
- Phytochemical Analysis, Antifungal, and Antioxidant Properties of Two Herbs (Advances in pharmacological and pharmaceutical sciences · 2023Article
- Non-Journal of fungi (Basel, Switzerland) · 2022Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionTargeting pathogenetic mechanisms, rather than essential processes, represents a very attractive alternative for the development of new antibiotics. This may be particularly important in the case of antimycotics, due to the urgent need for novel antifungal drugs and the paucity of selective fungal targets. The opportunistic pathogenic fungus Candida albicans is the main etiological agent of candidiasis, the most common human fungal infection. These infections carry unacceptably high mortality rates, a clear reflection of the many shortcomings of current antifungal therapy, including the limited armamentarium of antifungal agents, their toxicity and the emergence of resistance. Moreover, the antifungal pipeline is mostly dry. AREAS COVERED: This review covers some of the most recent progress toward understanding C. albicans pathogenetic processes and how to harness this information for the development of anti-virulence agents. The two principal areas covered are filamentation and biofilm formation, as C. albicans pathogenicity is intimately linked to its ability to undergo morphogenetic conversions between yeast and filamentous morphologies and to its ability to form biofilms. EXPERT OPINION: Filamentation and biofilm formation represent high value targets, yet are clinically unexploited, for the development of novel anti-virulence approaches against candidiasis. Although this has proved a difficult task despite increasing understanding at the molecular level of C. albicans virulence, there are some opportunities and prospects for antifungal drug development targeting these two important biological processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.